MedPath

Prednisone

Generic Name
Prednisone
Brand Names
Deltasone, Rayos, Winpred
Drug Type
Small Molecule
Chemical Formula
C21H26O5
CAS Number
53-03-2
Unique Ingredient Identifier
VB0R961HZT
Background

A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication

Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions
Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis
Associated Therapies
Palliative Treatment

Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2
Active, not recruiting
Conditions
Castration-Resistant Prostate Carcinoma
Metastatic Prostate Carcinoma
Stage IV Prostate Adenocarcinoma AJCC v7
Castration Levels of Testosterone
PSA Progression
Interventions
First Posted Date
2016-03-09
Last Posted Date
2024-11-28
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
196
Registration Number
NCT02703623
Locations
🇺🇸

MD Anderson in Katy, Houston, Texas, United States

🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

🇺🇸

MD Anderson in Sugar Land, Sugar Land, Texas, United States

Leflunomide for Maintenance of Remission in IgG4 Related Disease

Phase 4
Completed
Conditions
Immunoglobulin G4 Related Sclerosing Disease
Interventions
First Posted Date
2016-03-09
Last Posted Date
2019-03-06
Lead Sponsor
Chinese PLA General Hospital
Target Recruit Count
68
Registration Number
NCT02703194
Locations
🇨🇳

Chinese PLA General Hospital, Beijing, China

Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients

Phase 4
Conditions
ph+ Acute Lymphoblastic Leukemia
Interventions
First Posted Date
2016-02-24
Last Posted Date
2016-02-24
Lead Sponsor
Tongji Hospital
Target Recruit Count
40
Registration Number
NCT02690922
Locations
🇨🇳

Tongji hospital, Wuhan, Hubei, China

Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer

Phase 2
Terminated
Conditions
Prostate Cancer
Interventions
First Posted Date
2016-02-18
Last Posted Date
2021-04-09
Lead Sponsor
Prostate Cancer Clinical Trials Consortium
Target Recruit Count
9
Registration Number
NCT02685267
Locations
🇺🇸

Univesity of Wisconsin, Madison, Wisconsin, United States

🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

🇺🇸

The University of Chicago, Chicago, Illinois, United States

and more 2 locations

Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients

Phase 4
Completed
Conditions
Disorder Related to Renal Transplantation
Cytomegalovirus Infections
Interventions
First Posted Date
2016-02-17
Last Posted Date
2016-02-17
Lead Sponsor
Associação Médico Espírita de Botucatu
Target Recruit Count
48
Registration Number
NCT02683291

HD21 for Advanced Stages

First Posted Date
2016-01-22
Last Posted Date
2024-05-13
Lead Sponsor
University of Cologne
Target Recruit Count
1500
Registration Number
NCT02661503
Locations
🇩🇪

University Hospital of Cologne, Cologne, Germany

Modified MRCUKALLⅫ/ECOGE2993 Regimen for ALL

First Posted Date
2016-01-21
Last Posted Date
2017-06-19
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
100
Registration Number
NCT02660762
Locations
🇨🇳

Sun Yat-sen University Cancer Center, GuangZhou, Guangdong, China

Adjusted Steroids Therapy in Childerens With Idiopathic Nephrotic Syndrome

Phase 4
Conditions
Nephrotic Syndrome, Minimal Change
Interventions
First Posted Date
2016-01-07
Last Posted Date
2016-01-12
Lead Sponsor
Rabin Medical Center
Target Recruit Count
75
Registration Number
NCT02649413
Locations
🇮🇱

Shneider children Hospital Nephrology Institute, Petach-Tikva, Israel

Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib

Phase 2
Completed
Conditions
Diffuse Large B-Cell Lymphoma Unclassifiable
Interventions
First Posted Date
2015-12-21
Last Posted Date
2024-03-13
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
60
Registration Number
NCT02636322
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Efficacy and Safety of DAPSone as a Second-line Option in Adult Immune Thrombocytopenia

First Posted Date
2015-12-11
Last Posted Date
2017-07-26
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
216
Registration Number
NCT02627417
Locations
🇫🇷

Henri Mondor Hospital, Creteil, France

© Copyright 2025. All Rights Reserved by MedPath